The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

Female sex, antidepressant use, and type of health insurance significantly influence semaglutide initiation. (HealthDay News) — Sociodemographic, health care, and clinical factors are associated with ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

Additionally, semaglutide has been linked to improved cardiovascular outcomes in individuals with obesity but without diabetes, indicating its potential to address multiple health concerns ...

In a recent study published in the journal ... 2.4 mg semaglutide versus placebo on cardiovascular events in individuals with cardiovascular disease and overweight or obesity without diabetes.

In a recent study published in the journal ... effects of semaglutide on weight and anthropometric outcomes, as well as ...

The result from the SUMMIT study helps Lilly close the gap with Novo Nordisk, whose GLP-1 agonist semaglutide is already approved to reduce the risk of serious cardiovascular conditions in people ...

Significant associations for semaglutide initiation included being female, using certain medication classes including antidepressants, and being covered by a point-of-service plan. (HealthDay News ...